Antibody humanisation enables promising antibody candidates from non-human species to be modified so that they are applicable to humans.
LifeArc, a leading self-funded medical research charity, has joined iiCON as a consortium partner to make its expertise in the field of antibody humanisation available to research groups and organisations developing new antibodies for infectious diseases.
LifeArc’s expertise and track record of success in this field has helped transform the way many conditions are treated. With more than 90 antibodies humanised for 51 companies over the past 30 years, it has contributed to five marketed therapeutics. These results have been achieved by working with research teams and organisations to humanise and optimise the antibodies they have developed for clinical use – moving them closer towards patient impact.
LifeArc’s highly collaborative model supports innovation by de-risking innovation. If a project is selected for progression through its programme, LifeArc will take on the development risks and work closely with the team to progress the opportunity.
With huge untapped opportunity for antibodies in infectious diseases, this platform provides streamlined access to LifeArc’s leading humanisation capability coupled with iiCON’s highly-specialist infectious disease expertise that supports every stage of the product development journey from discovery to patient impact.
Find out more about LifeArc’s approach and leading antibody engineering capability here
For more information or to learn how your business can engage with this platform.